Recent advances in natriuretic peptides in congestive heart failure

Authors: Boerrigter G.; Burnett Jr J.C.

Source: Expert Opinion on Investigational Drugs, Volume 13, Number 6, 1 June 2004 , pp. 643-652(10)

Publisher: Informa Healthcare

Key:

- Free Content

- New Content

- Subscribed Content

- Free Trial Content

Abstract:

Atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) are secreted by the heart and play important roles in the compensation of congestive heart failure with their vasodilating, natriuretic, antiproliferative, lusitropic and neurohumoral-modulating properties. Based on these beneficial properties, exogenous BNP was developed as a new treatment for congestive heart failure and approved in the US for acute decompensated heart failure. New therapeutic strategies for heart failure that are currently being investigated include chronic subcutaneous BNP administration and intermittent BNP infusions. Furthermore, strategies combining exogenous BNP with an inhibitor of the BNP-degrading enzyme neutral endopeptidase could contribute to maximising the actions of BNP and reduce the amount of exogenous BNP needed.

Keywords: cyclic guanosine monophosphate; heart failure; natriuretic peptides; nesiritide; neurohumoral activation

Document Type: Review article

DOI: 10.1517/13543784.13.6.643

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$99.00 plus tax Refund Policy